AMGN34:BVMF
Amgen Inc. BDR
R$80.23
0.00%
(0.00) 1D
Sep 4, 4:56:00 PM GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN34...
Open
R$80.11
High
R$80.23
Low
R$80.11
Mkt. cap
236.38B
Avg. vol.
129.00
Volume
1.24K
52-wk high
R$83.06
52-wk low
R$47.76
Shares outstanding
540.63M
No. of employees
32K
Open
R$80.11
High
R$80.23
Low
R$80.11
Mkt. cap
236.38B
Avg. vol.
129.00
Volume
1.24K
52-wk high
R$83.06
52-wk low
R$47.76
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
MarketBeat
·
6 hours ago
TD Waterhouse Canada Inc. Sells 18,281 Shares of Amgen Inc. $AMGN
The Eastern Herald
·
9 hours ago
Amgen (NASDAQ:AMGN) Stock Dips 0.38% to $299.87 on August 28: Rate Fears Pinch Biotech Debt
Yahoo Finance
·
1 day ago
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Investing.com
·
1 day ago
Wells Fargo raises Amgen stock price target to $435 on drug trial outlook
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com